AAA Northeast’s Robert Sinclair joins The First trade to discuss the difficulties surrounding the summer travel businesses and what these businesses have done to adapt. ...
The busy calendar of June proved positive for drug approvals, with most scheduled events producing positive outcomes. New molecular entity, or NME, approval for the month totaled two, taking the total NME approvals for the year to 24.Among the NME approvals was Viela Bio Inc's (NASDAQ: VIE) lead drug Uplinza, which is indicated for neuromyelitis optica spectrum disorder. Although Upliinza will be pitched against Alexion Pharmaceuticals, Inc.'s (NASDAQ: ALXN) Soliris, the absence of black box warning gives the former an edge, H.C. Wainwright analyst Raghuram Selvaraju said in a note.There were disappointments too. Nabriva Therapeutics PLC's - ADR (NASDAQ: NBRV) antibiotic Contepa, as expectedly, was handed down a second complete response letter, or CRL, and AbbVie Inc's (NYSE: ABBV) eye disorder drug also faced rejection at the FDA altar.Here are the key PDUFA dates scheduled for July.Endo Awaits Nod For CCH In Cellulite * Company: BioSpecifics Technologies Corp. (NASDAQ: BSTC) and...
After being on the sidelines for payment processor Square Inc (NYSE: SQ), one analyst at Rosenblatt Securities turned bullish Wednesday. The Square Analyst: Kenneth Hill upgraded Square from Neutral to Buy and increased the price target from $69 to $121. The Square Thesis: Square's Cash App revenue excluding bitcoin is likely to increase more than three times over the next five years to $3.4 billion as the platform gains traction as a primary spending tool, Hill said in the upgrade note. (See his track record here.)The analyst said he expects continued user uptake on the Cash App to drive further engagement.Customers are increasingly gravitating toward Square's neobanking services, as reflected by the 9 million new monthly active users added in 2019 alone and acceleration through the pandemic, he said. Hill sees offerings like direct deposit boosting ecosystem engagement and Cash Card adoption and spend.The analyst expects second-quarter gross payment volume to...
Finding the right stock plays in the current environment is a challenge for every investor. The crisis sparked by the coronavirus and the unprecedented economic shutdown policies has defied all the rules, making it difficult to predict where a given stock may head. Fortunately, TipRanks has developed the tool you need to interpret the market.The Smart Score tool takes the range of TipRanks’ raw data, sorts it by 8 separate factors that are known to predict future stock behavior, and uses it to give each stock a single-digit store, on a scale of 1 to 10, indicating whether it is likely under- or overperform the general markets.Today, we’ll look at three stocks that have earned the highest Smart Scores. These are strong investments for that reason alone; but they also offer investors solid dividend payouts. Let’s find out what else makes them so compelling.OG&E Energy Corporation (OGE)We’ll start in the energy...
